Other substances

SARS-CoV-2 RBD-Fc

A COVID-19 candidate subunite vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

SARS-CoV-2 RBD-Fc is a recombinant subunit candidate vaccine containing RBD of SARS-CoV-2 Spike protein S1 domain and human IgG Fc fragment. Administered with Freund's (in)complete adjuvants (Liu et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
Spike protein Protein factor Animal model In vitro Mixed substance 		Vero E6 cells; Huh-7 cells; Balb/c mice 13.49

Elicited high anti-RBD (SARS-CoV-2) antibodies in mice. The produced antibodies potently neutralized SARS-CoV-2 pseudo- and live virus (with activity against SARS-CoV and SARS-related-CoVs, as well). SARS-CoV-2 RBD-specific sera from immunized mice also effectively blocked RBD-ACE binding (including RBD of various mutant versions of Spike protein) and inhibited SARS-CoV-2 infection in cell culture.

 Nov/27/2020

AI-suggested references

Link Publication date
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Jul/05/2021
Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
Nov/30/2021
Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Sep/22/2020
Export (.csv)